Dynavax Technologies Corp. DVAX

NAS: DVAX | ISIN: US2681582019   19/04/2024
11,80 USD (+4,06%)
(+4,06%)   19/04/2024

28 februari 2024 · Dynavax to Present at TD Cowen's 44th Annual Health Care Conference · Persbericht

22 februari 2024 · Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance · Persbericht

8 februari 2024 · Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024 · Persbericht

8 januari 2024 · Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights · Persbericht

4 januari 2024 · Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

2 november 2023 · Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance · Persbericht

26 oktober 2023 · Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 · Persbericht

19 oktober 2023 · Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference · Persbericht

6 september 2023 · Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference · Persbericht

3 augustus 2023 · Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance · Persbericht

20 juli 2023 · Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023 · Persbericht

30 mei 2023 · Dynavax to Present at Upcoming Investor Conferences · Persbericht

8 mei 2023 · Dynavax to Present at the JMP Securities Life Sciences Conference · Persbericht

2 mei 2023 · Dynavax Reports First Quarter 2023 Financial Results · Persbericht

18 april 2023 · Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023 · Persbericht

1 maart 2023 · Dynavax to Present at the Cowen 43rd Annual Health Care Conference · Persbericht

28 februari 2023 · Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine · Persbericht

23 februari 2023 · Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance · Persbericht

9 februari 2023 · Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 · Persbericht

31 januari 2023 · Dynavax Announces Uplisting to the Nasdaq Global Select Market · Persbericht

Mijn selecties